← Human Trials & Peer-Reviewed Studies
Nitrosamine and nicotine exposure after switching from filtered to unfiltered cigarette smoking: a cross-over clinical trial.
Plain-language guide to PMID 39433390 (2026): crossover randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 29 people.
Key Facts
- PMID
- 39433390
- Journal
- Tobacco control
- Year
- 2026
- Study type
- Randomized Controlled Trial
- Authors
- Appolon G et al. (11 authors)
- DOI
- 10.1136/tc-2024-058765
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).
The researchers conducted a cross-over, randomised clinical trial of 29 people who smoke to evaluate changes in biomarkers for nicotine and tobacco-specific nitrosamine exposure when switching between filtered and unfiltered cigarette smoking.
Why It Was Studied
The cellulose acetate filter is a plastic attachment on nearly all commercial cigarettes sold worldwide.
It is the main component of discarded cigarette butts, and the most prevalent waste item collected during urban and beach cleanups.
Who Took Part
According to the abstract, 29 people were involved.
PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized and crossover.
The people were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
In the crossover set-up each of the people took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.
What Was Measured
PubMed files the paper under topics including Nitrosamines, Nicotine, Tobacco Products, Cigarette Smoking and Biomarkers.
Author keywords: Cotinine, Public policy and Smoking topography.
What This Means in Plain Language
The paper is a randomized and crossover study of Therapeutic nicotine (patch, non-peptide) in 29 people.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2026 (Tobacco control), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.